The CRISPR patent estate is one of the most contested bodies of IP in modern biotechnology, and the ownership question still carries real commercial consequences for every founder building on gene-editing platforms today. Before you commit R&D budget, file a provisional patent, or enter a seed round conversation, you need a working map of who owns what and what that means for your product’s commercial viability. This guide gives you that map.
Key Takeaways
- The Broad Institute holds US patents covering CRISPR-Cas9 in eukaryotic cells; UC Berkeley holds broader but less therapeutically targeted claims.
- Freedom-to-operate (FTO) analysis is a formal legal opinion scoped to your specific Cas variant, delivery mechanism, and target cell type.
- European Patent Office rulings have diverged from US outcomes, creating jurisdiction-specific FTO profiles that matter if you’re commercialising in EU or UK markets.
- Cas12a, base editing, and prime editing carry distinct and in some cases less encumbered patent estates than Cas9.
- Most early-stage founders access CRISPR IP through sublicensing arrangements with platform companies, not direct licenses from primary IP holders.
Why the CRISPR Patent Estate Is Unusually Complex
Most biotech IP disputes resolve around a single assignee or a clear priority date. CRISPR doesn’t work that way. The foundational technology sits at the intersection of two parallel invention claims: Jennifer Doudna and Emmanuelle Charpentier’s 2012 Science paper describing the core biochemical mechanism, and Feng Zhang’s work at the Broad Institute demonstrating the system’s function in eukaryotic cells (cells with a nucleus, the cell type found in humans and most organisms relevant to therapeutic development).
Both groups filed patents. Both groups received them. The result is a split estate where the Broad Institute and UC Berkeley (representing the Regents of the University of California) hold distinct but overlapping claims. For you as a founder, this isn’t legal history. It’s an active variable in your commercial risk calculation.
The complexity compounds because both institutions have sublicensed rights to platform companies, those sublicensees have in turn partnered with startups, and continuation patents (new applications filed from an original patent that extend or narrow its claims) keep arriving at the USPTO and EPO. The CRISPR patent estate is not static. It’s growing.
The Broad vs. UC Berkeley Split: Commercial Implications
What the Courts Actually Decided
The USPTO interference proceeding, a process used to determine which of two parties first invented a claimed technology, concluded in 2017 in favour of the Broad Institute. The Federal Circuit upheld that ruling. The practical outcome: the Broad holds valid US patents covering CRISPR-Cas9 use in eukaryotic cells, the domain directly relevant to human therapeutics, animal models, and most agricultural crop applications.
UC Berkeley’s claims cover the core biochemical mechanism across all cell types, including prokaryotic cells (bacteria, without a nucleus). These claims are broader in scope but less targeted to the applications most founders are building toward. The distinction matters because it determines which institution you’ll need a license from depending on your specific product workflow.
| Factor | Broad Institute | UC Berkeley |
|---|---|---|
| Cell type scope | Eukaryotic cells | All cell types (including prokaryotic) |
| Therapeutic relevance | High (human, animal) | Moderate (broader but less targeted) |
| US legal status | Upheld by Federal Circuit | Valid, distinct from Broad claims |
| EPO status | Several claims revoked or narrowed | Some claims granted |
| Primary sublicensees | Editas Medicine | Intellia Therapeutics, CRISPR Therapeutics, ERS Genomics, Caribou Biosciences |
European and UK Jurisdiction Differences
The EPO has revoked or significantly narrowed several Broad Institute CRISPR claims that remain fully valid in the US. This creates a materially different FTO profile for companies commercialising primarily in European markets. A therapeutic program targeting EMA approval may face lower foundational IP encumbrance in Europe than an equivalent US-market product. That’s a strategic consideration worth quantifying before you choose your primary commercialisation geography.
UK-based founders face an additional layer. Post-Brexit, UK patent law follows EPO precedent for granted European patents, but UK filing and enforcement dynamics operate separately. If you’re building in a UK biotech cluster and planning a UK-first launch, your IP counsel needs CRISPR-specific EPO opposition experience, not just USPTO familiarity.
Freedom to Operate: What the Analysis Actually Involves
Freedom-to-operate analysis is a formal legal opinion, not a patent search, that assesses whether a specific product or process would infringe valid, enforceable claims in a given jurisdiction. The distinction matters because a patent search tells you what exists; an FTO opinion tells you whether what you’re building falls within those existing claims.
How to Conduct a CRISPR FTO Analysis: A Founder’s Framework
- Define your technical workflow precisely. Identify the Cas variant (Cas9, Cas12a, Cas13, base editor, prime editor), guide RNA design approach, delivery vector (viral, lipid nanoparticle, ribonucleoprotein), target cell type, and intended application (therapeutic, agricultural, research tool).
- Identify relevant patent families. For Cas9 therapeutics, this starts with Broad Institute US Patent 8,697,359 and its continuations, plus UC Berkeley’s US Patent 10,000,772. Your IP counsel will extend this search to MilliporeSigma (Merck), Vilnius University, and other assignees with claims in your specific area.
- Map independent claims against your workflow. Claim mapping compares each element of a patent’s independent claims (the broadest, standalone claims that don’t depend on other claims) against each step of your product process. If every element of a claim reads on your process, you’re within scope of that claim.
- Assess claim validity and enforceability. A patent can be valid but not enforceable, or subject to ongoing opposition proceedings that may narrow its scope. Your FTO opinion should reflect current legal status, not just grant status.
- Evaluate design-around options. Where infringement risk is identified, your counsel should outline whether a technical design-around (changing the Cas variant, delivery mechanism, or target) is feasible and what the IP consequences of that change would be.
- Document conclusions by jurisdiction. A US FTO conclusion does not transfer to Europe. Obtain separate opinions for each market you’re entering.
Commission an FTO analysis before significant R&D investment, before filing a patent application that references CRISPR methods, and before entering a licensing negotiation or fundraising round. Investors at Series A will expect to see a credible FTO position in your data room.
Licensing Pathways: From Direct Negotiation to Patent Pools
Sublicensing Through Platform Companies
Direct licensing from the Broad Institute or UC Berkeley is available primarily to well-capitalised companies with established commercial programs. Early-stage founders are more likely to access CRISPR IP through sublicensing arrangements with platform companies holding master licenses. Editas Medicine sublicenses Broad rights; Intellia Therapeutics, CRISPR Therapeutics, ERS Genomics, and Caribou Biosciences sublicense UCB-affiliated rights across different fields of use.
A field-of-use restriction defines the specific application area your sublicense covers. If your license covers ex vivo T-cell editing for oncology and you later expand into in vivo liver delivery, you’re outside your licensed field. Map your product roadmap against the field of use before signing, not after.
Patent Pools and Open-Access Limits
Patent pools, where multiple IP holders contribute claims into a shared licensing structure with standardised royalty terms, have been proposed for CRISPR and partially implemented in agricultural and global health contexts. The MPEG LA CRISPR patent pool is one structure worth reviewing if your application falls within its covered fields. Pool participation reduces transaction costs compared to bilateral negotiations, which matters when your legal budget is limited.
Open-access frameworks from institutions including the Broad offer royalty-free licenses for academic and non-commercial research. These explicitly exclude commercial product development. Using Addgene plasmid reagents in your early proof-of-concept work does not transfer any commercial license. If your IND-enabling studies build on data generated under an academic license, you need a separate commercial license before advancing.
Cas Variant Selection as an IP Decision
Cas9 carries the heaviest patent encumbrance of any CRISPR tool currently in development. Cas12a (also called Cpf1), Cas13, and base editing variants each sit within distinct patent families with different assignees and in some cases less contested ownership histories. Prime editing, developed from work at the Broad Institute, carries its own patent estate but may offer cleaner FTO in applications where Cas9-specific claims would otherwise apply.
CasX and other naturally occurring Cas proteins identified after the initial CRISPR-Cas9 filings may carry lower IP encumbrance, though this is application- and jurisdiction-dependent. The practical implication: technology selection decisions made in early R&D have downstream IP consequences that are expensive to reverse once a program is advanced. If two Cas variants offer comparable efficacy for your application, the one with lower patent encumbrance is the better commercial choice, assuming your FTO analysis confirms it.
Building Your IP Position Alongside FTO
FTO analysis tells you what you can do without infringing others’ patents. Your own patent strategy determines what others cannot do to you. Both are necessary. Neither substitutes for the other.
Patentable innovations in CRISPR programs typically arise from guide RNA design, delivery mechanisms, cell-type-specific applications, and manufacturing processes. You can build proprietary claims in these areas even when operating within a licensed foundational technology. Filing provisional patents before public disclosure of novel methods protects your innovation without prematurely narrowing your claims. Time full applications to coincide with key data milestones, and have IP counsel with CRISPR portfolio experience guide that sequencing.
Add a CRISPR IP risk register to your data room before approaching Series A investors. Document all identified patents, FTO opinions obtained, and any licensing agreements or active negotiations. Investors who understand biotech IP will ask for this. Investors who don’t will be reassured by it.
Frequently Asked Questions on CRISPR IP
Who owns the foundational CRISPR-Cas9 patents?
In the US, the Broad Institute holds patents covering CRISPR-Cas9 use in eukaryotic cells, upheld by the Federal Circuit. UC Berkeley holds separate patents covering the core biochemical mechanism across all cell types. Ownership differs by jurisdiction, with the EPO having revoked or narrowed several Broad claims.
What does freedom to operate mean in patents?
Freedom-to-operate (FTO) is a legal opinion confirming that a specific product or process does not infringe valid, enforceable third-party patent claims in a given jurisdiction. It is not a patent search. It requires claim mapping against your specific technical workflow.
Do I need a license from the Broad Institute to use CRISPR in my startup?
If your product uses CRISPR-Cas9 in eukaryotic cells and you’re commercialising in the US, a license from the Broad or a Broad sublicensee is likely required. The specific answer depends on your Cas variant, cell type, application, and geography. Commission a formal FTO opinion before assuming either way.
What is the CRISPR patent dispute between Broad and UC Berkeley?
Both institutions filed patents on CRISPR-Cas9 following parallel research programs. A USPTO interference proceeding determined that the Broad’s eukaryotic cell claims were patentably distinct from UC Berkeley’s broader claims, allowing both estates to coexist. The dispute has produced ongoing litigation and jurisdiction-specific outcomes at the EPO.
Can I use Cas12 or base editing to avoid Broad Institute patents?
Cas12a, base editing, and prime editing each fall under different patent families with different assignees. They may carry lower licensing costs or broader FTO in certain applications, but this is jurisdiction- and application-dependent. A technology-specific FTO analysis is required before drawing that conclusion for your program.
Disclaimer: This article provides strategic orientation on the CRISPR patent estate and does not constitute legal advice. FTO conclusions are jurisdiction-specific and subject to change as patents are granted, challenged, or expire. Engage qualified IP counsel with CRISPR portfolio experience for formal FTO opinions before making commercial, filing, or fundraising decisions.
- The CRISPR Patent Landscape: Navigating IP Minefields for Biotech Founders - November 16, 2026
- Restriction Site Mapping: A Practical Workflow for Cloning Strategy Design - November 9, 2026
- Innovate UK Grants for Biotech: Eligibility, Timelines, and Pitfalls - November 2, 2026
